FOR IMMEDIATE RELEASE
March 31, 2017

CONTACT: Gregg Gellman
ggellman@garwoodmedical.com
716.322.3222 x102

Garwood Medical Devices Announces Two Key Patents Granted
International Filings Also Completed

BUFFALO, NY – Garwood Medical Devices, a Western New York medical device company whose mission is advancing infection control through innovation, announced today that the U.S. Patent and Trademark Office has granted two important patents to the company.

“WOUND CARE BANDAGE AND METHOD OF HEALING”: Issue Date: March 14, 2017 U.S. Patent Number 9,592,160” details the EnerAid™ Active™ bandage, which aims to improve blood flow, and thus increase the rate at which ulcers, surgical and other wounds heal, while protecting the wound in a sterile environment. Garwood has filed for patent and trademark protection in key international markets, including Canada, China, the European Union and Vietnam.

“ELECTROCHEMICAL ERADICATION OF MICROBES ON SURFACES OF OBJECTS”: Issue Date: April 11, 2017 U.S. Patent Number 9,616,142 details an orthopaedic infection control technology and device that addresses the difficult challenge of eradicating bacterial biofilms (microorganisms that can adhere to surface joints) in orthopaedic and other implants.

Gregg Gellman, Vice President and Chief Operating Officer, stated, “These patents are significant because of the positive impact they will have in resolving costly and difficult challenges associated with wound healing and infection control.” Gellman further stated, “These two patent approvals from the United States Patent Office strengthen the Garwood Technology Platform, supporting our mission to advance infection control through innovation.”

“Our business model is based on accelerated development and commercialization of our internal and exclusively licensed technologies,” said Wayne Bacon, President and Chief Executive Officer of Garwood. “Leveraging the intellectual properties and technical capabilities of the University at Buffalo is critical to Garwood’s success.”

“BIG is proud to partner and support Garwood Medical Devices in the growth of their initiatives to overcome the challenges of wound healing and infection control,” said Brian McIlroy, executive director, Buffalo Institute for Genomics and Data Analytics (BIG). “This partnership aligns with BIG’s goals to advance precision medicine, and enhance the life sciences ecosystem and the related research atmosphere in the Buffalo Niagara region and beyond.”
**Wound Care**
Domestically, $11 billion is spent annually to treat patients who suffer from chronic wounds and infections. Over 8% of the US population is diabetic, and prone to chronic wounds, infections, and ulcers, and take far longer to heal than healthy patients.

**Implant Infections**
Over $14 billion is spent annually to treat implant infections in the United States. Orthopaedic implant infections can be disastrous for patients, as biofilms evade the immune system and are often resistant to conventional antibiotic therapy.

Garwood's technologies and devices have the potential to reduce patient morbidity and mortality while saving many billions of dollars per year worldwide.

The EnerAid™ Active™ wound care device and the B.E.S.T.™ biofilm eradication technology and devices are both planned for launch in 2018.

Garwood Medical Devices, LLC is a medical device company with a core mission to advance healing and infection control through innovation. Garwood has platform technologies that provide effective, efficient, and measurable electrical stimulation treatments for chronic wound healing, bone growth, and peri-prosthetic joint and other implant infections.

*For more information please visit www.garwoodmedical.com*